IGM Biosciences, Inc. (IGMS)
Largest Insider Buys in Sector
IGMS Stock Price History Chart
IGMS Stock Performance
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody …
Insider Activity of IGM Biosciences, Inc.
Over the last 12 months, insiders at IGM Biosciences, Inc. have bought $6.86M and sold $921,282 worth of IGM Biosciences, Inc. stock.
On average, over the past 5 years, insiders at IGM Biosciences, Inc. have bought $45.53M and sold $1.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $102.86M.
The last purchase of 97,473 shares for transaction amount of $937,632 was made by BAKER BROS. ADVISORS LP () on 2024‑03‑28.
List of Insider Buy and Sell Transactions, IGM Biosciences, Inc.
| 2024-09-13 | Sale | CEO AND PRESIDENT | 3,946 0.0062% | $11.54 | $45,532 | +23.62% | ||
| 2024-09-13 | Sale | CHIEF SCIENTIFIC OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +23.62% | ||
| 2024-09-13 | Sale | Head, Research & Autoimmunity | 1,487 0.0023% | $11.54 | $17,158 | +23.62% | ||
| 2024-09-13 | Sale | CHIEF MEDICAL OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +23.62% | ||
| 2024-09-13 | Sale | CHIEF FINANCIAL OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +23.62% | ||
| 2024-09-13 | Sale | CHIEF BUSINESS OFFICER | 925 0.0015% | $11.54 | $10,673 | +23.62% | ||
| 2024-09-13 | Sale | PRINCIPAL ACCOUNTING OFFICER | 469 0.0007% | $11.54 | $5,412 | +23.62% | ||
| 2024-07-25 | Sale | director | 15,132 0.0297% | $14.00 | $211,848 | -2.11% | ||
| 2024-06-14 | Sale | CEO AND PRESIDENT | 4,164 0.0067% | $7.58 | $31,544 | +54.81% | ||
| 2024-06-14 | Sale | CHIEF SCIENTIFIC OFFICER | 1,106 0.0018% | $7.58 | $8,378 | +54.81% | ||
| 2024-06-14 | Sale | CHIEF MEDICAL OFFICER | 1,570 0.0025% | $7.58 | $11,893 | +54.81% | ||
| 2024-06-14 | Sale | CHIEF FINANCIAL OFFICER | 1,570 0.0025% | $7.58 | $11,893 | +54.81% | ||
| 2024-06-14 | Sale | Head, Research & Autoimmunity | 1,570 0.0025% | $7.58 | $11,893 | +54.81% | ||
| 2024-06-14 | Sale | CHIEF BUSINESS OFFICER | 977 0.0016% | $7.58 | $7,401 | +54.81% | ||
| 2024-06-14 | Sale | PRINCIPAL ACCOUNTING OFFICER | 495 0.0008% | $7.58 | $3,750 | +54.81% | ||
| 2024-03-28 | 97,473 0.1653% | $9.62 | $937,632 | +0.31% | ||||
| 2024-03-27 | 27,844 0.0472% | $9.24 | $257,170 | +4.15% | ||||
| 2024-03-26 | 270,000 0.4372% | $8.26 | $2.23M | +11.18% | ||||
| 2024-03-14 | Sale | CEO AND PRESIDENT | 4,182 0.0073% | $10.17 | $42,533 | -5.00% | ||
| 2024-03-14 | Sale | CHIEF SCIENTIFIC OFFICER | 1,844 0.0032% | $10.17 | $18,754 | -5.00% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 3753480 6.3122% | $8.89 | 7 | 0 | ||
| Hambleton Julie | director | 2000 0.0034% | $8.89 | 1 | 3 | +104.4% |
| Topsoe Holding A/S | 10 percent owner | 5044295 8.4829% | $8.89 | 4 | 0 | +25.62% |
| Green Jeremy | 4500225 7.568% | $8.89 | 1 | 0 | <0.0001% | |
| Redmile Group, LLC | director | 2974186 5.0016% | $8.89 | 7 | 1 | +49.57% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $39.45M | 6.93 | 4.09M | +10.76% | +$3.83M | 0.28 | |
| T. Rowe Price | $37.52M | 6.59 | 3.89M | +19.26% | +$6.06M | 0.01 | |
| Artal Group S A | $29.73M | 5.22 | 3.08M | -0.65% | -$193,000.00 | 0.13 | |
| Redmile Group | $29.65M | 5.21 | 3.07M | +3.4% | +$974,032.41 | 0.3 | |
| Fidelity Investments | $12.71M | 2.23 | 1.32M | -22.44% | -$3.68M | <0.01 |